Cumberland Pharmaceuticals has initiated the clinical development of Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD). Cumberland has completed manufacturing and received clearance from the FDA for its investigational new drug (IND) submission and Phase II study associated with the product.
“Physicians and patients alike are eager for viable new treatment options for AERD to help relieve symptoms and restore quality of life. This ifetroban clinical program is a truly exciting development, supported by laboratory findings in animal models of the disease,” said Andrew White, MD, lead investigator for the trial and researcher from Scripps Clinic in San Diego.
Aspirin-exacerbated respiratory disease (AERD), also known as Samter’s Triad, is a respiratory disease involving chronic asthma and nasal polyposis that is worsened by aspirin or nonsteroidal anti-inflammatory drugs. Approximately one in 20 asthmatic adults (nearly 1 million patients in the United States) suffer from AERD and the disease awareness is growing within the medical community.
